Skip to main content

Study on Potentiation of ATRA Activity in HL-60 Cells by Targeting Methylation Enzymes | Chapter 2 | New Frontiers in Medicine and Medical Research Vol. 11

All Trans Retinoic Acid (ATRA) is a clinically established Differentiation Inducer (DI) for Acute Promyelocytic Leukemia (APL). Its efficacy in treating other kinds of Acute Myelocytic Leukemia (AML) is limited. ATRA targets the PML-RARA (promyelocytic leukemia/retinoic acid receptor-alpha)/DNA methyltransferase (DNMT)/Histone Deacetylase (HDAC) complex in APL, causing gene silencing to be lost and Terminal Differentiation to occur (TD). ATRA targeting of WT RARA as a single drug fails to modify the epigenetic modifications that prevent differentiation in other kinds of AML. When paired with DNMT inhibitors like 5-azacytidine, however, ATRA has better in vitro and clinical effectiveness against AML. The methylation enzyme complex (MMS), which includes Methionine Adenosyltransferase (MAT), Methyltransferase (MT), and S-Adenosylhomocysteine Hydrolase (SAHH), was previously shown to trigger differentiation in the AML M2 HL-60 cell line model. Differentiation Helper Inducers are inhibitors of the ternary methylation enzyme complex (DHIs). While they can't produce significant terminal differentiation on their own, they can help DIs work better. DHIs that destabilise SAHH enhance ATRA's ability to induce terminal differentiation in both sensitive and resistant HL-60 cells in vitro, according to this study. We also looked at Tyrosine Kinase Inhibitors (TKIs), which block the generation of SAHH's stabilising factor, and steroid analogues, which compete with SAHH's endogenous steroid stabilising factor. After exposure to 1(mu)M doses of ATRA, 72 percent of early passage (sensitive) HL-60 cells displayed induction of Terminal Differentiation (TD), whereas only 43 percent of late passage (resistant) cells did. Late passage HL-60 cell TD rose dramatically when ATRA was coupled with TKI imatinib mesylate or the steroid analogues resveratrol or (beta)-sitosterol, drugs with no innate capacity to induce differentiating, reaching 98 percent, 99 percent, and 94 percent of cells, respectively. Combinations of ATRA with cytotoxic chemotherapeutic drugs resulted in very minor improvements in TD percentages: ATRA plus topotecan: 76 percent; ATRA plus oxaliplatin: 63 percent; ATRA plus paclitaxel: 59 percent. ATRA's effects on an AML M2 cell line, and possibly other kinds of AML, were amplified when it was combined with drugs that interfere with the maintenance of the methyl group pool.


Author (S) Details

Ming C. Liau
CDA Therapeutics, CA, USA.

Jai-Hyun Kim
Chao Family Comprehensive Cancer Center, University of California, IrvineMedical Center, CA, USA.

John P. Fruehauf
Chao Family Comprehensive Cancer Center, University of California, IrvineMedical Center, CA, USA.


View Book :- https://stm.bookpi.org/NFMMR-V11/article/view/3688

Comments

Popular posts from this blog

A Prospective Study about Safety and Efficacy of Perioperative Lidocaine Infusion | Chapter 09 | New Horizons in Medicine and Medical Research Vol. 8

 Opioids cause clinically significant side effects such as respiratory depression, immunosuppression, muscle rigidity, negative inotropism, nausea, vomiting, hyperalgesia, urine retention, postoperative ileus, and drowsiness. Perioperative opioids are a major contributor to the United States' and other countries' opioid epidemics. Non-opioid analgesics, particularly lidocaine, are becoming more common for perioperative use as a result of this. A total of 185 adult patients were randomly assigned to one of two groups: control group I (105 patients) [fentanyl group] or group ii (80 patients) [opioid-free anaesthesia group]. Lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion intraoperatively, and 1.5-2 mg/kg/h infusion for 2-8 hours postoperatively were given to patients in both groups at anaesthetic induction. Intraoperatively, both groups received analgesic adjuvants such as diclofenac 75 mg, paracetamol 1 gm, and mgso4 30-50 mg/kg. If the mean arterial pressure (map)

A Brief Study of Middleware Technologies: Programming Applications and Management Systems | Chapter 15 | Novel Research Aspects in Mathematical and Computer Science Vol. 1

  Many platforms, services, applications, hardware, and operating systems are connected through the middleware layer. Because the middleware layer abstracts much low-level complexity and makes applications and software systems portable, it allows disparate systems to interface and function together in harmony. Middleware technologies enable software engineers to swiftly construct software systems and applications, allowing developers to focus on more important tasks. This chapter examines several types of middleware systems and discusses middleware capabilities, middleware operation, middleware's function in cloud-based systems, and the best middleware platforms to use. Middleware systems are widely utilised and can be found in practically any software system or application. Middleware programmes provide as a link between many sorts of systems and protocols. They serve as a mechanism for various systems. To successfully exchange information, it runs on a variety of operating system

Patients’ Perspective of Acute Post-operative Pain Management: A Multicentre Survey of Tertiary Hospitals in Maharashtra, India | Chapter 08 | New Horizons in Medicine and Medical Research Vol. 8

 When postoperative pain is adequately controlled, patients' satisfaction and patient-related outcomes (PROs) increase. Understanding the patients' perspective is crucial since it supports in the formulation of improvement strategies. Because wrong attitudes and assumptions might block pain alleviation, patients' attitudes and beliefs are critical. As a result, a multicenter study of patients' attitudes, beliefs, experiences, and satisfaction levels with acute postoperative pain management was done in Maharashtra's tertiary hospitals. In addition, the responses were examined to evaluate if the Acute Pain Service (APS) resulted in improved patient outcomes and satisfaction. A 13-item questionnaire adapted from previous studies was used to capture patients' experiences with postoperative pain treatment. The responses of 179 patients are included in the study. The findings revealed that 91.6 percent of patients experienced postoperative pain, with 75.5 percent